Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.
Epistemonikos ID: c85a0594991817ad1108ab7962b80614f31fb522
First added on: May 04, 2024